Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 67
Filter
1.
Int J Tuberc Lung Dis ; 22(7): 820-826, 2018 07 01.
Article in English | MEDLINE | ID: mdl-29914609

ABSTRACT

BACKGROUND: Chronic obstructive pulmonary disease (COPD) is a heterogeneous condition that can differ in its clinical manifestation, structural changes and response to treatment. OBJECTIVE: To identify subgroups of COPD with distinct phenotypes, evaluate the distribution of phenotypes in four related regions and calculate the 1-year change in lung function and quality of life according to subgroup. METHODS: Using clinical characteristics, we performed factor analysis and hierarchical cluster analysis in a cohort of 1676 COPD patients from 13 Asian cities. We compared the 1-year change in forced expiratory volume in one second (FEV1), modified Medical Research Council dyspnoea scale score, St George's Respiratory Questionnaire (SGRQ) score and exacerbations according to subgroup derived from cluster analysis. RESULTS: Factor analysis revealed that body mass index, Charlson comorbidity index, SGRQ total score and FEV1 were principal factors. Using these four factors, cluster analysis identified three distinct subgroups with differing disease severity and symptoms. Among the three subgroups, patients in subgroup 2 (severe disease and more symptoms) had the most frequent exacerbations, most rapid FEV1 decline and greatest decline in SGRQ total score. CONCLUSION: Three subgroups with differing severities and symptoms were identified in Asian COPD subjects.


Subject(s)
Dyspnea/epidemiology , Pulmonary Disease, Chronic Obstructive/epidemiology , Quality of Life , Aged , Asia/epidemiology , Cities , Cluster Analysis , Cohort Studies , Dyspnea/etiology , Factor Analysis, Statistical , Female , Follow-Up Studies , Forced Expiratory Volume , Humans , Male , Middle Aged , Phenotype , Pulmonary Disease, Chronic Obstructive/physiopathology , Risk Factors , Severity of Illness Index , Surveys and Questionnaires
2.
Allergy ; 73(11): 2192-2204, 2018 11.
Article in English | MEDLINE | ID: mdl-29672862

ABSTRACT

BACKGROUND: Exposure to environmental pollutants promotes Th2 cell responses. Aryl hydrocarbon receptor (AhR) activation aggravates allergic responses. Epithelium-derived thymic stromal lymphopoietin (TSLP), interleukin (IL)-25, and IL-33 are implicated in the dysregulation of Th2 immune responses in severe allergic asthma. METHODS: Bronchial biopsies of 28 allergic severe asthma and 6 mild asthma subjects from highly polluted areas were analyzed for AhR nuclear translocation (NT), cytokine expression, and gene activation. Cultured primary epithelial cells were stimulated with diesel exhausted particles (DEP) to determine AhR-mediated IL-33, Il-25, and TSLP synthesis and release. RESULTS: Primary bronchial epithelial cells exposed to DEP showed upregulation of IL-33, IL-25, and TSLP. These effects were abolished by knockdown of AhR by siRNA. Increased AhR/ARNT binding to promoters of IL-33, IL-25, and TSLP was found using chromatin immunoprecipitation (ChIP) assay. Allergic severe asthma with high AhR NT had higher bronchial gene and protein expression of IL-33, IL-25, and TSLP. These patients derived clinical benefit from anti-IgE treatment. CONCLUSION: Aryl hydrocarbon receptor activation by DEP mediates upregulation of IL-33, IL-25, and TSLP with Th2 activation, potentially linking environmental pollution and allergic severe asthma.


Subject(s)
Asthma/etiology , Asthma/metabolism , Cytokines/metabolism , Receptors, Aryl Hydrocarbon/metabolism , Respiratory Mucosa/immunology , Respiratory Mucosa/metabolism , Vehicle Emissions , Allergens/immunology , Antibodies, Anti-Idiotypic/pharmacology , Antibodies, Anti-Idiotypic/therapeutic use , Asthma/diagnosis , Asthma/therapy , Biopsy , Cytokines/genetics , Female , Fluorescent Antibody Technique , Gene Expression Regulation , Humans , Immunoglobulin E/immunology , Immunohistochemistry , Male , Middle Aged , Promoter Regions, Genetic , Protein Transport , Respiratory Function Tests , Respiratory Mucosa/pathology , Th2 Cells/immunology , Th2 Cells/metabolism , Thymic Stromal Lymphopoietin
3.
Oncogene ; 33(6): 756-70, 2014 Feb 06.
Article in English | MEDLINE | ID: mdl-23376851

ABSTRACT

Receptor tyrosine kinases (RTKs) are cell surface receptors that initiate signal cascades in response to ligand stimulation. Abnormal expression and dysregulated intracellular trafficking of RTKs have been shown to be involved in tumorigenesis. Recent evidence shows that these cell surface receptors translocate from cell surface to different cellular compartments, including the Golgi, mitochondria, endoplasmic reticulum (ER) and the nucleus, to regulate physiological and pathological functions. Although some trafficking mechanisms have been resolved, the mechanism of intracellular trafficking from cell surface to the Golgi is not yet completely understood. Here we report a mechanism of Golgi translocation of epidermal growth factor receptor (EGFR) in which EGF-induced EGFR travels to the Golgi via microtubule-dependent movement by interacting with dynein and fuses with the Golgi through syntaxin 6-mediated membrane fusion. We also demonstrate that the microtubule- and syntaxin 6-mediated Golgi translocation of EGFR is necessary for its consequent nuclear translocation and nuclear functions. Thus, together with previous studies, the microtubule- and syntaxin 6-mediated trafficking pathway from cell surface to the Golgi, ER and the nucleus defines a comprehensive trafficking route for EGFR to travel from cell surface to the Golgi and the nucleus.


Subject(s)
Cell Nucleus/metabolism , ErbB Receptors/metabolism , Golgi Apparatus/metabolism , Microtubules/metabolism , Qa-SNARE Proteins/metabolism , Cell Movement/physiology , Dyneins/genetics , Dyneins/metabolism , ErbB Receptors/antagonists & inhibitors , ErbB Receptors/genetics , Gene Knockdown Techniques , HeLa Cells , Humans , Protein Transport , Qa-SNARE Proteins/genetics , RNA, Small Interfering/administration & dosage , RNA, Small Interfering/genetics
4.
Int J Tuberc Lung Dis ; 16(12): 1674-9, 2012 Dec.
Article in English | MEDLINE | ID: mdl-23131268

ABSTRACT

OBJECTIVE: To determine whether the nucleic acid amplification (NAA) test on specimens collected by bronchoscopy improves the diagnostic accuracy of pulmonary tuberculosis (PTB) in sputum-negative patients. DESIGN: Bronchoscopy was performed among smear-negative PTB suspects to collect respiratory specimens to assess the efficacy and accuracy of the Amplified Mycobacterium Tuberculosis Direct (AMTD) test in the diagnosis of PTB. RESULTS: In 105 PTB suspects, 80 were finally excluded, of whom two were false-AMTD-positive. PTB (n = 25) was diagnosed in 10 patients culture-positive for Mycobacterium Tuberculosis (7/105 bronchial wash/bronchoalveolar lavage [BW/BAL] specimens, 6/315 expectorated sputum specimens [2 positive in 2 patients; 1 positive in 2 patients], and one with both), and in 15 patients with improvement after anti-tuberculosis treatment. Among the 25 PTB patients, 20 were AMTD-positive, of whom four were culture-positive. Three AMTD-negative patients were culture-positive. The sensitivity and specificity of AMTD were respectively 80.0% and 97.5%. The diagnostic yield was higher in respiratory specimens obtained at bronchoscopy and measured by AMTD than in conventional sputum or BW/BAL culture. CONCLUSION: NAA testing on specimens collected using bronchoscopy provides a highly efficient and reliable approach in the diagnosis of PTB in smear-negative PTB suspects.


Subject(s)
Bronchoalveolar Lavage Fluid/microbiology , Bronchoscopy , DNA, Bacterial/isolation & purification , Mycobacterium tuberculosis/genetics , Mycobacterium tuberculosis/isolation & purification , Nucleic Acid Amplification Techniques , Sputum/microbiology , Tuberculosis, Pulmonary/diagnosis , Adult , Aged , Aged, 80 and over , Chi-Square Distribution , False Positive Reactions , Female , Humans , Male , Middle Aged , Predictive Value of Tests , ROC Curve , Reagent Kits, Diagnostic , Sensitivity and Specificity , Tuberculosis, Pulmonary/microbiology , Young Adult
5.
Ann Oncol ; 23(8): 2082-2087, 2012 Aug.
Article in English | MEDLINE | ID: mdl-22730101

ABSTRACT

BACKGROUND: Bone metastases are common in patients with advanced non-small-cell lung cancer (NSCLC) and can have devastating consequences. Preventing or delaying bone metastases may improve outcomes. PATIENTS AND METHODS: This study evaluated whether zoledronic acid (ZOL) delayed disease progression or recurrence in patients with controlled stage IIIA/B NSCLC after first-line therapy. Patients received vitamin D and calcium supplementation and were randomized to i.v. ZOL (every 3-4 weeks) or no treatment (control). The primary end point was progression-free survival (PFS). RESULTS: No significant intergroup differences were observed in PFS or overall survival (OS). Median PFS was 9.0 months with ZOL versus 11.3 months for control. Fifteen ZOL-treated (6.6%) and 19 control patients (9.0%) developed bone metastases. Estimated 1-year OS was 81.8% for each group. ZOL safety profile was consistent with previous clinical data, but with higher discontinuations versus control. Fifteen ZOL-treated (6.6%) and five control patients (2.3%) had renal adverse events. Two cases of osteonecrosis of the jaw were reported. CONCLUSIONS: ZOL did not significantly affect PFS or OS in stage IIIA/B NSCLC patients with controlled disease, with a trend toward worsening PFS in the longer-term follow-up. Few patients experienced bone metastases, possibly limiting the potential ZOL impact on disease course.


Subject(s)
Bone Neoplasms/prevention & control , Bone Neoplasms/secondary , Carcinoma, Non-Small-Cell Lung/drug therapy , Diphosphonates/therapeutic use , Imidazoles/therapeutic use , Lung Neoplasms/drug therapy , Adult , Aged , Aged, 80 and over , Calcium/administration & dosage , Carcinoma, Non-Small-Cell Lung/pathology , Carcinoma, Non-Small-Cell Lung/secondary , Dietary Supplements , Female , Humans , Lung Neoplasms/pathology , Male , Middle Aged , Neoplasm Staging , Vitamin D/administration & dosage , Young Adult , Zoledronic Acid
6.
Eur Respir J ; 37(2): 310-7, 2011 Feb.
Article in English | MEDLINE | ID: mdl-20562122

ABSTRACT

The self-management of asthma can improve clinical outcomes. Recently, mobile telephones have been widely used as an efficient, instant personal communication tool. This study investigated whether a self-care system will achieve better asthma control through a mobile telephone-based interactive programme. This was a prospective, controlled study in outpatient clinics. From 120 consecutive patients with moderate-to-severe persistent asthma, 89 were eventually recruited for the study, with 43 in the mobile telephone group (with a mobile telephone-based interactive asthma self-care system). In the mobile telephone group, mean ± sem peak expiratory flow rate significantly increased at 4 (378.2 ± 9.3 L·min⁻¹; n = 43; p = 0.020), 5 (378.2 ± 9.2 L·min⁻¹; n = 43; p = 0.008) and 6 months (382.7 ± 8.6 L·min⁻¹; n = 43; p = 0.001) compared to the control group. Mean±sem forced expiratory volume in 1 s significantly increased at 6 months (65.2 ± 3.2% predicted; n = 43; p < 0.05). Patients in the mobile telephone group had better quality of life after 3 months, as determined using the Short Form-12® physical component score, and fewer episodes of exacerbation and unscheduled visits than the control group. Patients in the mobile telephone group significantly increased their mean daily dose of either systemic or inhaled corticosteroids compared with the control group. The mobile telephone-based interactive self-care system provides a convenient and practical self-monitoring and -management of asthma, and improves asthma control.


Subject(s)
Adrenal Cortex Hormones/therapeutic use , Anti-Asthmatic Agents/therapeutic use , Asthma/drug therapy , Cell Phone , Self Care/methods , Female , Humans , Leukotriene Antagonists/therapeutic use , Male , Middle Aged , Quality of Life , Respiratory Function Tests , Telemedicine , Treatment Outcome
7.
Int J Tuberc Lung Dis ; 14(5): 627-34, 2010 May.
Article in English | MEDLINE | ID: mdl-20392358

ABSTRACT

SETTING: Several matrix metalloproteinase (MMP) polymorphisms favouring the development of lung fibrosis after pulmonary tuberculosis (TB) have been described. OBJECTIVE: To investigate the association of MMP-1, MMP-9 and MMP-12 polymorphisms with the development of fibrosis in pulmonary TB. DESIGN: We studied 49 normal subjects and 98 TB patients. We analysed the association between MMP polymorphisms and clinical indices of lung fibrosis by serial chest radiography for 1 year after completion of treatment. RESULTS: The frequency of the MMP-1(-1607G) polymorphism was significantly higher in TB patients with moderate to advanced pulmonary fibrosis than in those with minimal to mild fibrosis. Having at least one -1607G MMP-1 polymorphism increased the risk of moderate and advanced fibrosis respectively by 5.04 (95%CI 1.25-20.30) and 9.87 (95%CI 2.39-40.88) fold. There was no association of MMP-9(-1562T) and MMP-12(Asn357Ser) polymorphisms with lung fibrosis. The production of MMP-1 from monocytes stimulated by interleukin-1 beta was increased in subjects with the 1G allele genotype compared to the 2G/2G genotype. CONCLUSIONS: Patients with MMP-1(-1607G) polymorphism are more vulnerable to more extensive lung fibrosis 1 year after anti-tuberculosis treatment. This may be related to increased MMP-1 activity, leading to enhanced destruction of the matrix with subsequent fibrosis.


Subject(s)
Genetic Predisposition to Disease , Lung/pathology , Matrix Metalloproteinase 1/genetics , Tuberculosis, Pulmonary/complications , Adult , Aged , Antitubercular Agents/therapeutic use , Female , Fibrosis , Follow-Up Studies , Humans , Male , Matrix Metalloproteinase 12/genetics , Matrix Metalloproteinase 9/genetics , Middle Aged , Polymorphism, Genetic , Prospective Studies , Risk Factors , Time Factors , Tuberculosis, Pulmonary/drug therapy
8.
Thorac Cardiovasc Surg ; 58(2): 102-7, 2010 Mar.
Article in English | MEDLINE | ID: mdl-20333573

ABSTRACT

BACKGROUND: This retrospective study aimed to determine the factors leading to obstructive granulation tissue formation after the placement of a self-expandable metallic stent (SEMS) in patients with benign tracheal disease. METHODS: From 2001 to 2007, a total of 67 patients (age: 62.1 +/- 15.4 years; range: 23-87 years) with benign tracheal disease received 75 ultraflex SEMS in our institution. RESULTS: There were 35 SEMSs complicated by obstructive granulation tissue formation out of the 75 stents placed in patients with tracheal disease, giving an incidence of 47.8 % (32/67 patients). The median time until developing granulation tissue was 106 days (IQR, 46-396). Structural airway obstruction prior to SEMS implantation independently predicted obstructive granulation tissue formation after SEMS implantation (odds ratio: 3.84; 95 % CI: 1.01-8.7; P = 0.04). Time to granulation tissue detection was shorter in patients with structural airway obstruction before SEMS implantation (structural airway obstruction vs. dynamic collapse airway: median [IQR] 95 [38-224, n = 26] vs. 396 days [73-994, n = 9]; P = 0.02). CONCLUSIONS: Obstructive granulation tissue formation is not uncommon after SEMS implantation and structural airway obstruction prior to SEMS implantation is an independent predictor. Although SEMS implantation should be restricted to a select population, it may be placed in patients not suitable for surgical intervention or rigid bronchoscopy with anesthesia because of poor pulmonary function.


Subject(s)
Airway Obstruction/etiology , Foreign-Body Reaction/etiology , Granulation Tissue/pathology , Stents/adverse effects , Tracheal Stenosis/therapy , Adult , Aged , Aged, 80 and over , Airway Obstruction/diagnosis , Airway Obstruction/pathology , Airway Obstruction/therapy , Bronchoscopy , Foreign-Body Reaction/diagnosis , Foreign-Body Reaction/pathology , Foreign-Body Reaction/therapy , Humans , Kaplan-Meier Estimate , Logistic Models , Middle Aged , Odds Ratio , Patient Selection , Retrospective Studies , Risk Assessment , Risk Factors , Time Factors , Tomography, X-Ray Computed , Tracheal Stenosis/diagnosis , Young Adult
9.
Ann Oncol ; 21(2): 217-222, 2010 Feb.
Article in English | MEDLINE | ID: mdl-20110292

ABSTRACT

BACKGROUND: Identification of appropriate markers for predicting clinical benefit with erlotinib in non-small-cell lung cancer (NSCLC) may be able to guide patient selection for treatment. This open-label, multicentre, phase II trial aimed to identify genes with potential use as biomarkers for clinical benefit from erlotinib therapy. METHODS: Adults with stage IIIb/IV NSCLC in whom one or more chemotherapy regimen had failed were treated with erlotinib (150 mg/day). Tumour biopsies were analysed using gene expression profiling with Affymetrix GeneChip microarrays. Differentially expressed genes were verified using quantitative RT-PCR (qRT-PCR). RESULTS: A total of 264 patients were enrolled in the study. Gene expression profiles found no statistically significant differentially expressed genes between patients with and without clinical benefit. In an exploratory analysis in responding versus nonresponding patients, three genes on chromosome 7 were expressed at higher levels in the responding group [epidermal growth factor receptor (EGFR), phosphoserine phosphatase (PSPH) and Rap guanine nucleotide exchange factor 5 (RAPGEF5)]. Independent quantification using qRT-PCR validated the association between EGFR and PSPH overexpression, but not RAPGEF5 overexpression, and clinical outcome. CONCLUSIONS: This study supports the use of erlotinib as an alternative to chemotherapy for patients with relapsed advanced NSCLC. Genetic amplification of the EGFR region of chromosome 7 may be associated with response to erlotinib therapy.


Subject(s)
Biomarkers, Tumor/genetics , Carcinoma, Non-Small-Cell Lung/drug therapy , Gene Expression Profiling , Lung Neoplasms/drug therapy , Quinazolines/therapeutic use , Adult , Aged , Aged, 80 and over , Antineoplastic Agents/adverse effects , Antineoplastic Agents/therapeutic use , Biomarkers, Pharmacological/analysis , Biomarkers, Pharmacological/metabolism , Biomarkers, Tumor/analysis , Biomarkers, Tumor/metabolism , Carcinoma, Non-Small-Cell Lung/diagnosis , Carcinoma, Non-Small-Cell Lung/genetics , Disease-Free Survival , Erlotinib Hydrochloride , Female , Gene Expression Regulation, Neoplastic/drug effects , Humans , Lung Neoplasms/diagnosis , Lung Neoplasms/genetics , Male , Middle Aged , Oligonucleotide Array Sequence Analysis , Prognosis , Quinazolines/adverse effects
10.
Int J Tuberc Lung Dis ; 13(3): 335-40, 2009 Mar.
Article in English | MEDLINE | ID: mdl-19275793

ABSTRACT

OBJECTIVES: To determine predictive factors for mortality among pulmonary tuberculosis (PTB) patients without human immunodeficiency virus (HIV) infection and in need of mechanical ventilation (TBMV). METHODS: From July 2004 to December 2005, 612 respiratory failure patients requiring mechanical ventilation were admitted to the intensive care unit (ICU) of Chang Gung Memorial Hospital, Taipei, Taiwan. Of these, 59 non-HIV-infected patients had active PTB as the primary cause. Mortality rates were measured in TBMV patients and predictors were investigated. Incidence of treatment delay for nosocomial pneumonia was compared between survivors and fatalities. RESULTS: Of the 59 patients with TBMV, 40 (67.8%) died in the ICU. Multi-organ failure syndrome (OR 8.59, 95%CI 1.85-101.27) and nosocomial pneumonia (OR 5.77, 95%CI 1.33-44.36) were independently associated with in-hospital mortality. Treatment delay >24 h for nosocomial pneumonia was significantly more frequent among fatalities than among survivors (19/26, 73.1% vs. 0/3, 0%; P = 0.033). CONCLUSION: Nosocomial pneumonia in TB patients with respiratory failure is associated with a poor prognosis; this appears to be further aggravated by delays in appropriate treatment. Measures to prevent nosocomial pneumonia should be carefully instituted and treatment for nosocomial pneumonia should be started promptly among such patients.


Subject(s)
Respiratory Insufficiency/mortality , Tuberculosis, Pulmonary/mortality , APACHE , Aged , Aged, 80 and over , Cross Infection/mortality , Humans , Middle Aged , Multivariate Analysis , Prognosis , Respiration, Artificial , Respiratory Insufficiency/etiology , Respiratory Insufficiency/therapy , Retrospective Studies , Tuberculosis, Pulmonary/complications
11.
Eur Respir J ; 32(3): 651-9, 2008 Sep.
Article in English | MEDLINE | ID: mdl-18508824

ABSTRACT

The application of a supervised endurance exercise training programme in a home setting offering convenience and prolonged effects is a challenge. In total, 48 patients were initially assessed by the incremental shuttle walk test (ISWT), spirometry and the Short Form-12 (SF-12) quality-of-life questionnaire, and then every 4 weeks for 3 months thereafter and again after 1 yr. During the first 3 months, 24 patients in the cell phone group were asked to perform daily endurance walking at 80% of their maximal capacity by following the tempo of music from a program installed on a cell phone. The level of endurance walking at home was readjusted monthly according to the result of ISWT. In the control group, 24 patients received the same protocol and were verbally asked to take daily walking exercise at home. Patients in the cell phone group significantly improved their ISWT distance and duration of endurance walking after 8 weeks. The improvements in ISWT distance, inspiratory capacity and SF-12 scoring at 12 weeks persisted until the end of the study, with less acute exacerbations and hospitalisations. In the present pilot study, the cell phone-based system provides an efficient, home endurance exercise training programme with good compliance and clinical outcomes in patients with moderate-to-severe chronic obstructive pulmonary disease.


Subject(s)
Cell Phone , Exercise Therapy/methods , Pulmonary Disease, Chronic Obstructive/rehabilitation , Aged , Exercise Tolerance , Female , Humans , Male , Music , Patient Compliance , Pilot Projects , Quality of Life
12.
Eur Respir J ; 31(5): 1019-23, 2008 May.
Article in English | MEDLINE | ID: mdl-18184680

ABSTRACT

Stent implantation has been reported to facilitate liberation from mechanical ventilation in patients with respiratory failure due to central airway disease. The present retrospective cohort study sought to evaluate the risk and benefit of stent implantation via bronchoscopy without fluoroscopic guidance in mechanically ventilated patients. From July 2001 to September 2006, 26 patients with acute respiratory failure were recruited. A bronchoscope was inserted through a mouth guard into the space between the tracheal wall and the endotracheal tube. A guide wire was inserted via the flexible bronchoscope to the lesion site. The bronchoscope was reintroduced through the endotracheal tube. Under bronchoscopic visualisation, the delivery catheter was advanced over the guide wire to deploy the stent. These procedures were successfully performed in 26 patients, with 22 stents placed in the trachea and seven in the main bronchus. Of the 26 patients, 14 (53.8%) became ventilator independent during their stay in the intensive care unit. Severe pneumonia was the most common cause, in seven (58.3%) out of 12 patients, for continued ventilator dependence after stenting. Granulation tissue formation was found in seven patients during the follow-up period. It is concluded that metallic stents can be safely implanted without fluoroscopic guidance in patients with respiratory failure, to facilitate ventilator independence.


Subject(s)
Airway Obstruction/surgery , Bronchoscopy/methods , Respiratory Insufficiency/surgery , Stents , Aged , Airway Obstruction/complications , Bronchoscopy/adverse effects , Cohort Studies , Female , Humans , Male , Middle Aged , Respiration, Artificial , Respiratory Insufficiency/etiology , Retrospective Studies , Ventilator Weaning
13.
Inflamm Res ; 56(5): 195-203, 2007 May.
Article in English | MEDLINE | ID: mdl-17588135

ABSTRACT

OBJECTIVE: The phagocytic recognition and clearance of the recruited inflammatory cells with prolonged survival play a pivotal role in relieving tissue inflammation and maintaining tissue homeostasis. Transgenic mice expressing Bcl-2 in mature neutrophils demonstrated that Bcl-2 attenuated neutrophil apoptosis, while the homeostasis of the neutrophil population was essentially unaffected. This result suggests that clearance of neutrophils with prolonged survival operates independently from apoptosis. Owing to the constitutive and inducible expression of Bcl-2 homologue, A1 in human neutrophils and the intolerance of preparation for the isolated human neutrophils with prolonged survival, the human promyelocytic HL60-A1 transfectants were established to study the mechanism of phagocytic recognition/clearance of the cells with prolonged survival. MATERIALS AND METHODS: The non-apoptotic cells with prolonged survival were enriched by serum withdrawal for five days and negatively isolated by annexin V-binding beads. Then, the cells were labeled with a fluorogenic marker. Monocyte-derived macrophages (MDM) were co-cultured to perform the phagocytosis assay, and flow cytometry was employed to determine the phagocytic index. RESULTS: In the serum-free condition, the phagocytic index of HL60-A1 transfectants was little different from that of the HL60-EGFP control, despite showing a significantly lower degree of apoptosis. While the phagocytic index of HL60-EGFP control was significantly correlated with the degree of apoptosis, the index of the HL60-A1 transfectants was less relevant to it. The phagocytic index for the annexin V-positive cells did not distinguish the two cell types. However, the phagocytic index for the annexin V-negative cells from the HL60-A1 transfectants was increased with age in days. Preincubation of MDM with the scavenger receptor inhibitor, Oxi-LDL, and the inhibitory antibodies against alphavbeta3, CD14 and CD36 surface molecules could attenuate the phagocytic recognition of the annexin V-positive HL60 cells but not the annexin V-negative A1 transfectants with prolonged survival. CONCLUSIONS: This study thus suggests that a mechanism unrelated to apoptosis exists, which mediates the phagocytic clearance of the non-apoptotic cells with prolonged survival and may be associated with A1 function in the myeloid cells.


Subject(s)
Apoptosis/physiology , Neutrophils/pathology , Phagocytosis/physiology , Proto-Oncogene Proteins c-bcl-2/genetics , Apoptosis/drug effects , Cell Survival/drug effects , Cell Survival/physiology , Cells, Cultured , Gene Expression Regulation , Green Fluorescent Proteins/genetics , Green Fluorescent Proteins/metabolism , HL-60 Cells , Humans , Lipoproteins, LDL/pharmacology , Macrophages/metabolism , Macrophages/pathology , Minor Histocompatibility Antigens , Neutrophils/metabolism , Phagocytosis/drug effects , Proto-Oncogene Proteins c-bcl-2/metabolism , Transfection
14.
Cancer Gene Ther ; 13(7): 706-19, 2006 Jul.
Article in English | MEDLINE | ID: mdl-16514421

ABSTRACT

To ensure the success of systemic gene therapy, it is critical to enhance the tumor specificity and activity of the promoter. In the current study, we determined that topoisomerase IIalpha promoter is selectively activated in breast cancer cells. An element containing an inverted CCAAT box (ICB) was shown to be responsible for the breast cancer specificity. When the ICB-harboring topoisomerase IIalpha minimal promoter was linked with an enhancer sequence from the cytomegalovirus immediate early gene promoter (CMV promoter), this composite promoter, CT90, exhibited activity comparable to or higher than the CMV promoter in breast cancer cells in vitro and in vivo, yet expresses much lower activity in normal cell lines and normal organs than the CMV promoter. A CT90-driven construct expressing BikDD, a potent proapoptotic gene, was shown to selectively kill breast cancer cells in vitro, and to suppress mammary tumor development in an animal model of intravenously administrated, liposome-delivered gene therapy. Expression of BikDD was readily detectable in the tumors but not in the normal organs (such as heart) of CT90-BikDD-treated animals. The results indicate that liposomal CT90-BikDD is an effective systemic breast cancer-targeting gene therapy.


Subject(s)
Antigens, Neoplasm/genetics , Apoptosis Regulatory Proteins/genetics , Breast Neoplasms/therapy , DNA Topoisomerases, Type II/genetics , DNA-Binding Proteins/genetics , Genetic Therapy , Membrane Proteins/genetics , Mutation , Response Elements/genetics , Animals , Apoptosis Regulatory Proteins/metabolism , Breast Neoplasms/genetics , Cell Line, Tumor , Cytomegalovirus/genetics , Enhancer Elements, Genetic/genetics , Female , Gene Expression , Genetic Vectors , Humans , Liposomes , Membrane Proteins/metabolism , Mice , Mice, Nude , Mitochondrial Proteins , Neoplasms, Experimental
15.
J Pharm Pharmacol ; 55(1): 115-23, 2003 Jan.
Article in English | MEDLINE | ID: mdl-12625875

ABSTRACT

We have investigated the role of protein kinase C (PKC) and nuclear factor-kappaB (NF-kappaB) in cyclooxygenase-2 (COX-2) expression caused by Staphylococcus aureus lipoteichoic acid in RAW 264.7 macrophages. A phosphatidylcholine-phospholipase C (PC-PLC) inhibitor (D-609) and a phosphatidylinositol-phospholipase C (PI-PLC) inhibitor (U-73122) attenuated lipoteichoic acid-induced COX-2 expression, while a phosphatidate phosphohydrolase inhibitor (propranolol) had no effect. Two PKC inhibitors (Go 6976 and Ro 31-8220) and the NF-kappaB inhibitor, pyrrolidine dithiocarbamate (PDTC), also attenuated lipoteichoic acid-induced COX-2 expression. Lipoteichoic acid resulted in a decrease in PKC activity in the cytosol and an increase in PKC activity in membranes. The lipoteichoic acid-induced translocation of p65 NF-kappaB from the cytosol to the nucleus was inhibited by D-609, U-73122, Go 6976, Ro 31-8220, and PDTC, but not by propranolol. The results suggested that lipoteichoic acid might have activated PC-PLC and PI-PLC to induce PKC activation, which in turn initiated NF-kappaB activation, and finally induced COX-2 expression in RAW 264.7 macrophages.


Subject(s)
Isoenzymes/biosynthesis , Lipopolysaccharides/pharmacology , Macrophages/physiology , NF-kappa B/pharmacology , Prostaglandin-Endoperoxide Synthases/biosynthesis , Protein Kinase C/pharmacology , Teichoic Acids/pharmacology , Animals , Cell Culture Techniques , Cyclooxygenase 2 , Mice , Phosphatidylcholines/chemistry , Phosphatidylinositols/chemistry , Phospholipases/chemistry , Staphylococcus aureus/pathogenicity
16.
Br J Pharmacol ; 134(7): 1539-47, 2001 Dec.
Article in English | MEDLINE | ID: mdl-11724761

ABSTRACT

1. There are increased numbers of circulating CD34(+) progenitor cells for eosinophils in patients with atopic asthma, with a further increase following allergen exposure or spontaneous worsening of asthma. We investigated the expression of IL-5 and IL-5Ralpha receptor in circulating CD34(+) progenitor cells in allergic asthmatics and the effects of corticosteroids. 2. Using double-staining techniques, up to 50% of CD34(+) cells expressed intracellular IL-5, and by RT - PCR, there was significant expression of IL-5 mRNA. When cultured in a semi-liquid methylcellulose medium, there were more eosinophil colony-forming units grown from asthmatic non-adherent mononuclear cell depleted of T cells in the presence of the growth factors GM-CSF, SCF and IL-3, but not of IL-5. 3. An anti-IL-5Ralpha receptor antibody and an anti-sense IL-5 oligonucleotide reduced the number of eosinophil colony forming units. No IL-5 mRNA or protein expression on T cells was observed in asthmatics or normal subjects. In the presence of growth factors including IL-5, there were significantly greater colony numbers with eosinophilic lineage grown from either asthmatics or normal subjects. 4. Dexamethasone (10(-6) M) suppressed IL-5 mRNA and protein expression in CD34(+) cells, and reduced eosinophil colony-forming units in asthmatics, but not in normal subjects. Dexamethasone did not change the expression of IL-5Ralpha on CD34(+) cells. 5. We conclude that there is increased expression of IL-5 on blood CD34(+) cells of patients with asthma and that this expression may auto-regulate eosinophilic colony formation from these progenitor cells. Corticosteroids inhibit the expression of IL-5 in circulating CD34(+) progenitor cells.


Subject(s)
Asthma/physiopathology , Cell Differentiation/drug effects , Cell Division/drug effects , Eosinophils/drug effects , Interleukin-5/pharmacology , Adult , Antibodies, Monoclonal/pharmacology , Antigens, CD34/immunology , Asthma/pathology , DNA, Antisense/pharmacology , Dexamethasone/pharmacology , Eosinophils/cytology , Eosinophils/immunology , Female , Gene Expression , Glucocorticoids/pharmacology , Humans , Interleukin-5/genetics , Interleukin-5/physiology , Leukocytes, Mononuclear/cytology , Leukocytes, Mononuclear/drug effects , Leukocytes, Mononuclear/immunology , Male , RNA, Messenger/genetics , RNA, Messenger/metabolism , Receptors, Interleukin/immunology , Receptors, Interleukin-5 , Stem Cells/drug effects
17.
Br J Pharmacol ; 134(3): 543-52, 2001 Oct.
Article in English | MEDLINE | ID: mdl-11588108

ABSTRACT

1. This study investigated the role of protein kinase C (PKC) and transcription factor nuclear factor-kappaB (NF-kappaB) in cyclooxygenase-2 (COX-2) expression caused by lipoteichoic acid (LTA), a cell wall component of the gram-positive bacterium Staphylococcus aureus, in human pulmonary epithelial cell line (A549). 2. LTA caused dose- and time-dependent increases in COX-2 expression and COX activity, and a dose-dependent increase in PGE(2) release in A549 cells. The LTA-induced increases in COX-2 expression and COX activity were markedly inhibited by dexamethasone, actinomycin D or cyclohexamide, but not by polymyxin B, which binds and inactivates endotoxin. 3. The phosphatidylcholine-phospholipase C (PC-PLC) inhibitor (D-609) and the phosphatidate phosphohydrolase inhibitor (propranolol) reduced the LTA-induced increases in COX-2 expression and COX activity, while phosphatidylinositol-phospholipase C inhibitor (U-73122) had no effect. The PKC inhibitors (Go 6976, Ro 31-8220 and GF 109203X) and NF-kappaB inhibitor, pyrrolidine dithiocarbamate (PDTC), also attenuated the LTA-induced increases in COX-2 expression and COX activity. 4. Treatment of A549 cells with LTA caused an increase in PKC activity in the plasma membrane; this stimulatory effect was inhibited by D-609, propranolol, or Go 6976, but not by U-73122. 5. Exposure of A549 cells to LTA caused a translocation of p65 NF-kappaB from the cytosol to the nucleus and a degradation of IkappaB-alpha in the cytosol. Treatment of A549 cells with LTA caused NF-kappaB activation by detecting the formation of NF-kappaB-specific DNA-protein complex in the nucleus; this effect was inhibited by dexamethasone, D-609, propranolol, Go 6976, Ro 31-8220, or PDTC. 6. These results suggest that LTA might activate PC-PLC and phosphatidylcholine-phospholipase D to induce PKC activation, which in turn initiates NF-kappaB activation, and finally induces COX-2 expression and PGE(2) release in human pulmonary epithelial cell line.


Subject(s)
Epithelial Cells/drug effects , Epithelial Cells/enzymology , Isoenzymes/biosynthesis , Lipopolysaccharides/pharmacology , Lung/enzymology , NF-kappa B/biosynthesis , Prostaglandin-Endoperoxide Synthases/biosynthesis , Signal Transduction/drug effects , Staphylococcus aureus , Teichoic Acids/pharmacology , Cyclooxygenase 2 , Dinoprostone/biosynthesis , Dose-Response Relationship, Drug , Epithelial Cells/microbiology , Humans , Lung/cytology , Lung/drug effects , Lung/physiology , Membrane Proteins , Signal Transduction/physiology , Tumor Cells, Cultured
18.
Life Sci ; 69(11): 1333-44, 2001 Aug 03.
Article in English | MEDLINE | ID: mdl-11521757

ABSTRACT

To investigate the effect of neutrophil adherence to epithelial cells on the release of interleukin 8 (IL-8), we measured neutrophil adherence in the presence or absence of IFN-gamma+TNF-alpha+IL-1beta (cytomix) stimulation on cultured A549 epithelial cells. The extent of neutrophil adherence to A549 epithelial cells was measured and the concomitant production of IL-8 and nitrite were assayed. The roles of adhesion molecules and nitrite in modulation of neutrophil adherence were examined by pretreatment with oversaturating ICAM-1 blocking antibody and L-NAME (1 mM), respectively. There was a time-dependent spontaneous and cytomix-induced release of IL-8 from epithelial cells, as well as a time-dependent increase in the magnitude of neutrophil adherence to epithelial cells. Stimulation of epithelial cells with cytomix induced a further increase in neutrophil adherence. Pretreatment with oversaturated ICAM-1 monoclonal antibody inhibited neutrophil adherence with or without cytomix stimulation. The inhibition of neutrophil adherence to epithelial cells with ICAM-1 monoclonal antibody or a semipermeable membrane downregulated the release of IL-8 with or without cytomix stimulation. Stimulation with cytomix decreased nitrite production. Both neutrophil adherence and L-NAME pretreatment significantly inhibited the production of nitrite. The inhibition of neutrophil adherence to epithelial cells with ICAM-1 monoclonal antibody or a semipermeable membrane upregulated nitrite production. Pretreatment with L-NAME failed to modify the spontaneous release of IL-8, but significantly enhanced the response to adherence and cytomix. In conclusion, endogenous nitric oxide may play a role in preventing neutrophil adherence to lung epithelial cells, thus modulating concomitant IL-8 release.


Subject(s)
Cell Adhesion/physiology , Interleukin-8/metabolism , Lung/metabolism , Neutrophils/physiology , Nitric Oxide/physiology , Antibodies, Monoclonal/pharmacology , Cell Adhesion/drug effects , Cell Survival/drug effects , Cell Survival/physiology , Cells, Cultured , Drug Combinations , Epithelial Cells/drug effects , Epithelial Cells/metabolism , Humans , Intercellular Adhesion Molecule-1/immunology , Interferon-gamma/pharmacology , Interleukin-1/pharmacology , Lung/cytology , Lung/drug effects , NG-Nitroarginine Methyl Ester/pharmacology , Neutrophils/drug effects , Tumor Necrosis Factor-alpha/pharmacology
19.
Chang Gung Med J ; 24(3): 159-66, 2001 Mar.
Article in English | MEDLINE | ID: mdl-11355083

ABSTRACT

BACKGROUND: We studied the correlation between exercise tolerance and pulmonary function, arterial blood gases, and ventilatory drive in patients with airflow limitation (AFL). METHODS: Forty-one patients (36 men, 5 women, mean age 63.6 +/- 10.3 years) with forced expiratory volume in one second (FEV1) < 75% and FEV1/forced vital capacity (FVC) < 75% were enrolled. All patients were clinically stable with no impairment of the lower extremities. On the first day of the study, pulmonary function test (PF), including FVC, FEV1, diffusion capacity (DLCO), and residual volume (RV)/total lung capacity (TLC) was measured by plethysmography. On the next day, ventilatory drive P0.1 were measured before drawing blood gases. Then, a 6-minute walking test with pulse-oxymetry and end tidal CO2 monitoring was performed. Ventilation efficiency (O2SATp & ETCO2) was recorded every 6 seconds during exercise. RESULTS: The walking distance (WD) was significantly correlated to PF: FVC%, FEV1%, DLCO%, and RV/TLC. There was also a significant correlation between resting arterial blood gases (PaO2, PaCO2, SatO2) and PF (FVC%, FEV1%, DLCO% and RV/TLC). The SatO2 at the end of exercise was highly correlated to PF (FVC%, FEV1%, DLCO% and RV/TLC). Gas exchange parameters: PaO2, PaCO2, O2SATa, O2SATp at rest, and O2SATp at the end of exercise were also significantly related to WD. CONCLUSION: The magnitude of exercise intolerance in patients with AFL was not only significantly correlated to the impairment of pulmonary function, but also closely related to gas exchange during exercise. Therefore, limitation of ventilation could be identified earlier using an exercise test.


Subject(s)
Exercise Test , Exercise Tolerance , Lung Diseases, Obstructive/physiopathology , Aged , Female , Humans , Male , Middle Aged , Oximetry , Pulmonary Gas Exchange , Respiratory Function Tests
20.
Int J Tuberc Lung Dis ; 5(3): 283-91, 2001 Mar.
Article in English | MEDLINE | ID: mdl-11326829

ABSTRACT

SETTING: Peripheral blood monocytes (PBM) are the main source of alveolar macrophages, which have an upregulation of inducible nitric oxide synthase (iNOS) in pulmonary tuberculosis (TB). TNF-alpha and IL-1 beta are thought to be involved in the immune response to mycobacterial infection. OBJECTIVE: To identify whether iNOS expression and cytokine release of PBM are upregulated and have a connection in TB infection. DESIGN: The expression of iNOS immunoreactivity on PBM from TB patients and normal subjects was measured by loading with anti-macrophage iNOS polyclonal primary antibody analyzed by flow cytometry. Expression of iNOS mRNA in PBM was detected by RT-PCR. The spontaneous generation of nitrite and cytokines (IL-1 beta and TNF-alpha) by cultured monocytes was also determined. RESULTS: Compared to normal subjects, iNOS immuno-reactivity, the capacity for spontaneous nitrite generation and the level of TNF-alpha or IL-1 beta secretion of PBM were significantly higher in TB patients. The amount of nitrite, TNF-alpha and IL-1 beta released from PBM of TB patients was inhibited by NG-monomethyl-L-arginine (L-NMMA), a competitive inhibitor of NOS. The level of iNOS immunoreactivity on PBM was highly correlated with nitrite generation both in all the subjects studied and in TB patients alone. Spontaneous TNF-alpha production showed a stronger correlation with nitrite production than with IL-1 beta. CONCLUSION: The NO and cytokine synthase activities of monocytes appear to be concomitantly upregulated in response to mycobacterial infection. The enhanced NO generation by monocytes in TB patients may play an autoregulatory role in amplifying the synthesis of pro-inflammatory cytokines.


Subject(s)
Interleukin-1/metabolism , Leukocytes, Mononuclear/metabolism , Nitric Oxide Synthase/metabolism , Tuberculosis, Pulmonary/metabolism , Tumor Necrosis Factor-alpha/metabolism , Female , Flow Cytometry , Humans , Male , Middle Aged , Nitric Oxide/physiology , Nitric Oxide Synthase Type II , RNA, Messenger/metabolism , Reverse Transcriptase Polymerase Chain Reaction , Tuberculosis, Pulmonary/blood , Up-Regulation
SELECTION OF CITATIONS
SEARCH DETAIL
...